Diabetes in African Americans: Unique pathophysiologic features

Current Diabetes Reports

Volumn 4, Issue 3, 2004, Pages 219-223

  Banerji, Mary Ann ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AUTOANTIBODY; BIGUANIDE DERIVATIVE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; NATEGLINIDE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; REPAGLINIDE; SULFONYLUREA;

AFRICAN AMERICAN; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIABETIC KETOACIDOSIS; DIET THERAPY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; REMISSION; REVIEW;

EID: 3142632133     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0027-3     Document Type: Review

References (55)

1. Harris MI, Flegal KM, Cowie CC, et al.: Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. Diabetes Care 1998, 21:518-524.
2. Brancati FL, Kao WH, Folsom AR, et al.: Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000, 283:2253-2259.
3. Smedley BD,Stith AY,Nelson AR, eds: The healthcare environment and its relation to disparities. In Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: Institute of Medicine; 2003:80-124. http://www.nap.edu/catalog/10260.html.
4. Banerji MA, Chaiken RL, Huey H, et al.: GAD antibody negative NIDDM in black subjects with diabetic ketoacidosis and increased frequency of human leukocyte antigen DR3 and DR4. Flatbush diabetes. Diabetes 1994, 43:741-745.
5. Banerji MA, Lebovitz HE: Remission in non-insulin-dependent diabetes mellitus: clinical characteristics of remission and relapse in black patients. Medicine 1990, 69:176-185.
6. Chaiken RL, Banerji MA, Pasmantier RM, et al.: Patterns of glucose and lipid abnormalities in black NIDDM subjects. Diabetes Care 1991, 14:1036-1042.
7. Banerji MA, Lebovitz HE: Insulin sensitive and insulin resistant variants in NIDDM. Diabetes 1989, 38:784-801.
8. Reaven GM: The role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
9. McFarlane SI, Banerji MA, Sowers JR: Insulin resistance and cardiovascular risk. J Clin Endocrinol Metab 2001, 86:713-718.
10. Morrison EY, Ragoobirsingh D, Thompson H, et al.: Phasic insulin dependent diabetes: manifestations and cellular mechanisms. J Clin Endocrinol Metab 1995, 80:1996-2001.
11. Adadevoh BK: 'Temporary diabetes' in adult Nigerians. Trans R Soc Trop Med Hyg 1968, 62:528-530.
12. Katakawa M, Aizawa T, Naka M, et al.: Long-term prognosis of islet cell antibody negative ketosis onset diabetes with subsequent non-insulin dependency. Diabetes Care 1999, 22:1584-1586.
13. Umpierrez GE, Casals MM, Gebhart SP, et al.: Diabetic ketoacidosis in obese African-Americans. Diabetes 1995, 44:790-795.
14. Sobngwi E, Vexiau P, Levy V, et al.: Metabolic and immunogenic prediction of long term remission in African patients either atypical diabetes. Diabet Med 2002, 19:832-835.
15. Maldonado M, Hampe CS, Gaur LK, et al.: Ketosis prone diabetes: a dissection of a heterogeneous syndrome using immunogenetic and beta-cell functional classification, prospective analysis and clinical outcomes. J Clin Endocrinol Metab 2003, 88:5090-5098.
16. Balasubramanian A, Zern JW, Hyman DJ, Pavlik V: New profiles of diabetic ketoacidosis: type 1 and type 2 diabetes and the effect of ethnicity. Arch Intern Med 1999, 159:2317-2322.
17. Umpierrez CF, Clark WS, Steen MT: Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises. Diabetes Care 1997, 20:479-483.
18. Banerji MA, Chaiken RL, Lebovitz HE: Long-term remission in NIDDM in blacks. Diabetes 1996, 45:337-341.
19. Kayashima T, Yamaguchi K, Konno Y, et al.: Effects of early introduction of intensive insulin therapy on the clinical course of non-obese NIDDM patients. Diabetes Res Clin Pract 1995, 28:119-125.
20. Ilkova H, Glaser B, Tackle A, et al.: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997, 20:1352-1356.
21. Singer DL, Hurwitz D: Long-term experience with sulphonylureas and placebo. N Engl J Med 1967, 277:450-456.
22. Rendell M, Zariello J, Drew HM, et al.: Recovery from decompensated non-insulin dependent diabetes mellitus: studies of C-peptide secretion. Diabetes Care 1981, 4:354-359.
23. Lev-Ran A: Trial of placebo in long term chlorpropamide treated diabetics. Diabetologia 1974, 10:197-200.
24. Genuth SM: Clinical remission in diabetes mellitus. Studies of insulin secretion. Diabetes 1970, 19:116-121.
25. Cheng TO, Jahraus RC, Traut EF: Extreme hyperglycemia and severe ketosis with spontaneous remission of diabetes mellitus. JAMA 1953, 152:1531-1533.
26. Peck FB Jr, Kirtley WR, Peck FB Sr: Complete remission of severe diabetes. Diabetes 1958, 7:93-97.
27. Retinopathy and nephropathy in patients with type 1 diabetes for four years after a trial of intensive therapy. The diabetes control and complications trial. Epidemiology of diabetes interventions and complications research group [no authors listed]. N Engl J Med 2000, 342:381-388.
28. Stratton IM, Adler AI, Neil HA, et al.: Association of glycaemia with macrovascular and microvascular complication of type 2 diabetes. UKPDS 350: prospective observational study. BMJ 2000, 321:405-412.
29. Khaw KT, Wareham N, Luben R, et al.: Glycated haemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001, 322:15-18.
30. Hirsch S, Norton M, Harrington P: Education increases rate of near normoglycemic remission in newly diagnosed NIDDM [abstract]. Diabetes 1995, 142 (suppl):25A.
31. Banerji MA, Chaiken RC, Lebovitz HE: Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes 1995, 44:466-470.
32. Aguilar-Bryan L, Bryan J, Nakazaki M: Of mice and men: K(ATP) channels and insulin secretion. Recent Prog Horm Res 2001, 56:47-68.
33. McFarlane SI, Chaiken RL, Hirsch S, et al.: Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta-cell function. Diabet Med 2001, 18:10-16.
34. Yi Jarvinen H: Glucose toxicity. Endocr Rev 1992, 13:415-431.
35. McGarry JD: What if Minkowski had been ageusic? An alternate angle on diabetes. Science 1992, 258:766-770.
36. Haffner SM, D'Agostino R Jr, Mykkanen L, et al.: Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999, 22:562-568.
37. Banerji MA, Buckley MC, Chaiken RL, et al.: Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord 1995, 19:846-850.
38. Taniguchi A, Fukushima M, Sakai M, et al.: The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients. Metabolism 2000, 8:1001-1005.
39. Grundy SM, Brewer HB, Cleeman JI, et al.: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
40. Genuth S, Alberti KG, Bennett P, et al.: Follow-up on report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
41. Falkner B, Kushner H, Tulenko T, et al.: Insulin sensitivity, lipids, and blood pressure in young American blacks. Arterioscler Thromb Vasc Biol 1995, 11:1798-1804.
42. Chaiken RL, Banerji MA, Huey H, Lebovitz HE: Do blacks with NIDDM have an insulin-resistance syndrome? Diabetes 1993, 42:444-449.
43. Saad MF, Lillioja S, Nyomba BL, et al.: Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991, 324:733-739.
44. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report [no authors listed]. Circulation 2002, 106:3143-3421.
45. Ford ES, Gale WH, Dietz WH: Prevalence of metabolic syndrome in US adults: findings of the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
46. Laaka HM, Laaksonen DE, Laaka TA, et al.: The metabolic syndrome and cardiovascular mortality in middle-aged men. JAMA 2002, 288:2709-2716.
47. Osei K, Rhinesmith S, Gaillard T, Schuster D: Is glycosylated hemoglobin A1c a surrogate for metabolic syndrome in nondiabetic, first-degree relatives of African-American patients with type 2 diabetes? J Clin Endocrinol Metab 2003, 88:4596-4601.
48. Schulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176.
49. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-activated signal pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 2003, 52:1-8.
50. Sinha R, Fisch G, Teague B, et al.: Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002, 346:802-810.
51. Arslanian S: Metabolic differences between Caucasian and African-American children and the relationship to type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15(suppl 1):509-517.
52. Bacha F, Saad R, Gungor N, et al.: Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors. J Clin Endocrinol Metab 2003, 88:2534-2540.
53. Steinberger J, Daniels SR: Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation 2003, 107:1448-1453.
54. Apedo MT, Sowers JR, Banerji M: Cardiovascular disease in adolescents with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15(suppl 1):519-523.
55. Banerji MA: Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus - 'Flatbush diabetes'. J Pediatr Endocrinol Metab 2002, 15(supp) 1):493-501.